位置:成果数据库 > 期刊 > 期刊详情页
塞来昔布对人鼻咽癌CNE-2细胞生长抑制及放射增敏研究
  • ISSN号:1004-4221
  • 期刊名称:《中华放射肿瘤学杂志》
  • 时间:0
  • 分类:R730.53[医药卫生—肿瘤;医药卫生—临床医学] R730.55[医药卫生—肿瘤;医药卫生—临床医学]
  • 作者机构:[1]三峡大学第一临床医学院宜昌市中心人民医院肿瘤科三峡大学肿瘤研究所临床部,宜昌443002, [2]三峡大学医学院免疫学部, [3]三峡大学分子生物学研究所
  • 相关基金:国家自然科学基金面上项目(30772590)
中文摘要:

目的研究塞来昔布对人鼻咽癌细胞系CNE-2细胞生长影响及有无放射增敏作用。方法(1)细胞生长抑制研究:用MTT法检测细胞生长抑制,流式细胞术检测细胞周期分布及凋亡,透射电子显微镜观察细胞凋亡形态,sP法检测细胞COX-2表达。(2)放射增敏研究:随机设置照射对照、药物对照、单纯照射、药物+照射组,其中成克隆实验单次照射2、4、6、8、10Gy,细胞周期分布和凋亡实验单次照射6Gy。结果塞来昔布显著抑制CNE-2细胞生长并呈浓度和时间依赖性,IC50为80μmol/L。细胞周期分布显示G0+G1期细胞显著升高(47.03±2.76:56.17±1.95,t=4.68,P=0.010),而S、G2+M期细胞明显下降(33.07±1.86:24.87±1.76,t=5.54,P=0.010;19.30±0.53:17.73±0.83,t=2.75,P=0.050)并呈浓度依赖性。凋亡率显著增高(1.57±0.47:10.47±0.31,t=27.39,P=0.000)并呈浓度依赖性。电镜观察到细胞皱缩、核质浓缩、核碎裂等凋亡形态学改变。SP法检测塞来昔布显著下调CNE-2中COX.2表达[17.48±0.34、12.82±0.51(t=13.20,P=0.00)]。塞来昔布的放射增敏比(D0值比为1.74:1.52)为1.15。4个组别细胞周期分布结果显示单纯照射、药物+照射组的G2+M期细胞明显高于照射对照、药物对照组(68.00±1.65、54.27±5.74、17.60±0.80、14.86±1.23,t=47.70,P=0.000;t=11.63,P=0.000),且单纯照射与药物+照射组间也不同(t=3.99,P=0.020);单纯照射、药物+照射组的细胞凋亡率也明显高于照射对照、药物对照组(4.83±0.97、9.50±1.35、1.33±0.36、2.28±0.42,t=4.67,P=0.01;t=8.81,P=0.000),且单纯照射与药物+照射组也不同(t=4.85,P=0.010)。结论塞来昔布能抑制人鼻咽癌CNE-2细胞生长和诱导凋亡,其机制可能涉及COX-2依赖途径。塞来昔

英文摘要:

Objective To investigate the growth inhibition and radiosensitization of Celecoxib in human nasopharyngeal carcinoma cell line CNE-2. Methods CNE-2 growth inhibition by Celecoxib was evaluated by MTT method. Apoptosis-related changes in morphology were observed by transmission electron microscopy (TEM). Cell cycle distribution and apoptosis rate were measured by flowcytometry (FCM). The expression of COX-2 protein was observed by SP method after the treatment of Celecoxib. Cells were randomly planted into four groups : irradiation control ( Ci), drug group ( Cd), irradiation group ( R), and Celecoxih plus irradiation group (D ± R). Single irradiation of 2,4,6,8, and 10 Gy were administered for colonogenic assay. Cell cycle distribution and apoptosis rate were analyzed at 6 Gy irradiation. Results The growth of CNE-2 cell was inhibited by celecoxib in a dose-and time-dependent manner, the IC50 was 80 μmol/L. After the treatment, cell ratio of G0 and G1 phases was increased ( 47.03 ± 2.76 vs 56.17 ± 1.95 , t = 4.68 , P =0.010) ,whereas the ratio of S and G2/M phases was decreased (33.07 ± 1.86 vs 24.87 ± 1.76 ,t =5.54 ,P = 0.010 ; 19.30 ± 0. 53: 17.73 ± 0.83, t = 2.75, P = 0.050) , and the apoptosis rate was increased ( 1.57 ± 0.47:10.47± 0.31, t = 27.39, P = 0. 000)in a dose-dependent manner. Apoptosis with nuclear chromatin condensation ,fragmentation and cell shrinkage was found by TEM. SP method showed that Celeib decreased COX-2 expression ( 17.48 ± 0.34 vs 12.82 ± 0.51, t = 13.20, P = 0.00). The sensitivity ratio ( DO ) was 1.15. FCM showed that the percentage of cells in G2/M phase was significanty more in R and D + R groups than in Ci and Cd groups (68.00 ± 1.65,54.27 ± 5.74,17.60 ± 0.80,14.86 ± 1.23, t = 47.70,P = 0.000 ; t = 11.63, P = 0. 000), and also significantly different between R group and D+ R group ( t = 3.99, P = 0. 020). The apoptosis rate was higher in R and D + R groups than Ci and Cd groups(4.83 ±0.97,9.50 ±

同期刊论文项目
同项目期刊论文
期刊信息
  • 《中华放射肿瘤学杂志》
  • 中国科技核心期刊
  • 主管单位:中国科协
  • 主办单位:中华医学会
  • 主编:
  • 地址:北京朝阳区潘家园南里17号医学院肿瘤医院
  • 邮编:100021
  • 邮箱:cjron@cma.org.cn
  • 电话:010-67700737 87788294
  • 国际标准刊号:ISSN:1004-4221
  • 国内统一刊号:ISSN:11-3030/R
  • 邮发代号:82-240
  • 获奖情况:
  • 国内外数据库收录:
  • 被引量:16100